Abstract:Human genome sequencing studies have identified numerous loci associated with complex diseases, including Alzheimer’s disease (AD). However, translating human genetic and genomic findings (i.e., genome‐wide association studies [GWAS]) to pathobiology and therapeutic discovery remains a major challenge. Today, artificial intelligence and deep learning approaches that identify new risk genes and drug targets from human genome sequencing findings are enabling a more complete mechanistic understanding of disease biology. This is facilitating more rapid development of targeted therapeutic interventions for AD. We presented a network topology‐based deep learning framework to identify disease‐associated genes (NETTAG). NETTAG integrates multi‐genomics data and the human protein‐protein interactome to infer putative risk genes and drug targets impacted by GWAS loci. Specifically, we leveraged non‐coding GWAS loci effects on expression quantitative trait loci (eQTLs), histone‐QTLs, transcription factor binding‐QTLs, enhancers and CpG islands, promoter regions, open chromatin, and promoter flanking regions. The fundamental premise of NETTAG is that disease risk genes exhibit distinct functional characteristics compared to non‐risk genes, and can therefore be distinguished by their aggregated genomic features under the human protein interactome. Applying NETTAG to the latest AD GWAS data, we identified 156 putative AD‐risk genes (i.e., APOE, BIN1, GSK3B, MARK4, and PICALM). We showed that predicted risk genes are: 1) significantly enriched in AD‐related pathobiological pathways, 2) more likely to be differentially expressed in transcriptomes and proteomes of AD brains, and 3) enriched in druggable targets with approved medicines. Specifically, we showed that NETTAG‐predicted genes (e.g., MEF2D, CPLX2, KLF4, ACTL6B, P2RX7 and etc.) are differentially expressed in AD‐associated microglia and astrocytes from single‐nuclei RNA‐sequencing data of human postmortem brains with varying degrees of AD neurobiology. Via network‐based prediction, we identified multiple repurposable drug candidates (i.e., choline, deferoxamine and ibudilast) for potential treatment of AD. Our findings suggest that understanding human pathobiology and therapeutic development could benefit from network‐based deep learning methodology that utilizes GWAS findings with multimodal genomic analyses.

Identification of Novel Immune-Relevant Drug Target Genes for Alzheimer's Disease by Combining Ontology Inference with Network Analysis.

Identifying Shared Diagnostic Genes and Mechanisms in Vascular Dementia and Alzheimer's Disease Via Bioinformatics and Machine Learning

Discovery of Potential Drug Targeting Key Genes in Alzheimer's Disease: Insights from Transcriptome Analysis and Molecular Docking

Identification of Novel Drug Targets for Alzheimer's Disease by Integrating Genetics and Proteomes from Brain and Blood.

Discovery of Potential Drug Targeting Key Genes in Alzheimer’s Disease: Insights from Transcriptome Analysis and Molecular Docking

Identification of novel drug targets for Alzheimer’s disease by integrating genetics and proteomes from brain and blood

Genes related to neurotransmitter receptors as potential biomarkers for Alzheimer's disease

Network Proximity-based computational pipeline identifies drug candidates for different pathological stages of Alzheimer's disease

Drug Repositioning for Alzheimer's Disease Based on Systematic 'omics' Data Mining.

Integrated Identification of Key Genes and Pathways in Alzheimer’s Disease Via Comprehensive Bioinformatical Analyses

Protein-protein interaction network analysis for the identification of novel multi-target inhibitors and target miRNAs against Alzheimer's disease

Identification of Immune Cells and Key Genes associated with Alzheimer's Disease

A Network‐based Deep Learning Framework Translates GWAS and Multi‐Omics Findings to Pathobiology and Drug Repurposing for Alzheimer’s Disease

An Integrated Brain-Specific Network Identifies Genes Associated with Neuropathologic and Clinical Traits of Alzheimer's Disease.

Integrated Bioinformatic Analysis and Validation Identifies Immune Microenvironment-Related Potential Biomarkers in Alzheimer’s Disease

AI-DrugNet: A network-based deep learning model for drug repurposing and combination therapy in neurological disorders

Comprehensive Analysis Reveals A Six-Gene Signature and Associated Drugs in Alzheimer Disease

Identification of novel risk genes for Alzheimer's disease by integrating genetics from hippocampus

Identifying risk genes and therapeutics for Alzheimer’s disease through integration multi‐omics and drug‐perturbation signatures

Network Medicine Approach for Analysis of Alzheimer's Disease Gene Expression Data.

Discovery of combinational targets for Alzheimer’s disease based on traditional Chinese medicinal prescription (654.10)